Response to Lancet study on HRT use and breast cancer risk

The news confirms current guidelines by The National Institute for Health and Care Excellence (NICE) which notes a small increase in risks.

A study published in The Lancet indicates an increased risk of breast cancer for women using some types of Hormone Replacement Therapy (HRT) for five years.

The news confirms current guidelines by The National Institute for Health and Care Excellence (NICE) which notes a small increase in risks.

Researchers analysed data from 58 previous studies from around the world that involved more than 108,000 women who went on to develop breast cancer.

Wellbeing of Women CEO, Janet Lindsay, said:  “We welcome this new study  which is in keeping with The National Institute for Health and Care Excellence (NICE) guidelines that show a small increase in developing breast cancer with HRT.

“We now also know that the increased risk last longer after discontinuing HRT than was previously thought.

“It is very important for women to be fully informed before deciding what treatments they may wish to take to help them manage their menopausal symptoms.

“All women vary but for some it can be debilitating and affect their quality of life. As well as helping with menopausal symptoms HRT also offers benefits to bone and cardiovascular health,  too. We encourage women to talk through the options with their GP before making a choice about treatment.

“It is also important to remember that lifestyle factors such as obesity and alcohol intake are associated with a greater risk of developing breast cancer compared to taking HRT.”

Please read full statement by RCOG and BMS, here.

SHARE